Mallinckrodt. Mallinckrodt Pharmaceuticals plc is an Irish-American manufacturer of specialty pharmaceuticals (namely, adrenocorticotropic hormone), generic drugs and imaging agents. [2] In 2017, it had 5,500 employees and sales of $3.2 billion, of which $2.9 billion was from the U.S. healthcare system. [3] Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates. This site is an online medical resource intended to provide scientifically accurate, evidence-based, and balanced medical information on Mallinckrodt products. /PRNewswire/ -- Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics. About Us Solving complex challenges with a diverse product portfolio Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products. Listening for Needs, Delivering Solutions | Mallinckrodt Pharmaceuticals combined with Endo in 2025 to better serve customers and improve outcomes for the patients we support. The merger and corporate makeover represent a fresh start for Mallinckrodt and Endo, which have both faced significant financial pressure in recent years over their alleged roles in the opioid.